Bayer and CuraGen in two alliances

Bayer (DAX:BAYG) and CRGN entered two drug development alliances. Under a 15-year obesity and diabetes agreement, CRGN will deliver to BAYG 80 targets validated by CRGN's functional genomics

Read the full 282 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE